Skip to main content
Nordic's follicular lymphoma drug nabs FDA fast-track status
6/14/2018

The FDA designated fast-track status to Nordic Nanovector's Phase IIb Betalutin, or 177Lu-lilotomab satetraxetan, being developed to treat patients with relapsed or refractory follicular lymphoma after two or more prior systemic therapies.

Full Story: